Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Phase 1/2 Study of TP-3654, a Selective PIM1 Kinase Inhibitor: Preliminary Data Showed Clinical Activity and Cytokine Reductions in Relapsed/Refractory Myelofibrosis Patients

Blood (2023) 142 (Supplement 1): 626.

https://doi.org/10.1182/blood-2023-180164

Published: 2023

Journal Articles

A Phase 1 Study of PIT565, a First-in-Class, Anti-CD3, Anti-CD19, Anti-CD2 Trispecific Antibody in Patients with Relapsed and/or Refractory B-Cell Malignancies

Blood (2023) 142 (Supplement 1): 3099.

https://doi.org/10.1182/blood-2023-179061

Published: 2023

Journal Articles

Phase 1/2 First-in-Human Study of the Menin-MLL Inhibitor DSP-5336 in Patients with Relapsed or Refractory Acute Leukemia

Blood (2023) 142 (Supplement 1): 2911.

https://doi.org/10.1182/blood-2023-179252

Published: 2023

Journal Articles

Mechanism of Late Recurrences of Chronic Myeloid Leukemia after Discontinuation of TKI Therapy: BCR::ABL1 Ins35bp Loss-of-Function Splicing Mutation and Regulatory T Cells

Yuki Fujioka, Junichiro Yuda, Naoto Takahashi

Blood (2023) 142 (Supplement 1): 6344.

https://doi.org/10.1182/blood-2023-185710

Published: 2023

Journal Articles

Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia

Blood (2023) 141 (17): 2114–2126.

https://doi.org/10.1182/blood.2022017333

Published: 2023

Includes: Supplemental data

Journal Articles

Preliminary Data from the Phase I/II Study of TP-3654, a Selective Oral PIM1 Kinase Inhibitor, in Patients with Myelofibrosis Previously Treated with or Ineligible for JAK Inhibitor Therapy

Firas El Chaer, James McCloskey, Lindsay A.M. Rein, Randy A. Brown, Steven D. Green, Jeffrey J. Pu, Shuichi Shirane, Kazuya Shimoda, Michiko Ichii, Junichiro Yuda, Joseph Scandura, Sujan Kabir, Jason M Foulks, Jian Mei, Huyuan Yang, Mark Wade, Carl Stapinski, Claudia Lebedinsky, Raajit K Rampal

Blood (2022) 140 (Supplement 1): 594–595.

https://doi.org/10.1182/blood-2022-159086

Published: 2022

Journal Articles

Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients with Acute Leukemia with and without Mixed-Lineage Leukemia (MLL)-Rearrangement (R) or Nucleophosmin 1 (NPM1) Mutation (m)

Naval Daver, Takayuki Ikezoe, Justin Watts, Naoko Hosono, Yoshiaki Ogawa, Yasushi Miyazaki, Harry P. Erba, John Affinito, Emily Brooks, Ken Eguchi, Hongliang Cai, Bo Xu, Jay Stoudemire, Matthew Hitron, Akinobu Watanabe, Philip Komarnitsky, Junichiro Yuda

Blood (2022) 140 (Supplement 1): 3371–3372.

https://doi.org/10.1182/blood-2022-167674

Published: 2022

Journal Articles

A Practice-Oriented Genome Profiling Study with the Novel Halo-Shape Annealing and Defer-Ligation Enrichment (HANDLE) System : HM-Screen-JAPAN02

Blood (2022) 140 (Supplement 1): 10722–10724.

https://doi.org/10.1182/blood-2022-159351

Published: 2022

Journal Articles

Genomic Analysis of NPM1 Mutation and KMT2A ( MLL )-Rearrangement/Amplification in Japanese Patients with Acute Myeloid Leukemia: Hematologic Malignancies (HM)-Screen-Japan 01

Blood (2021) 138 (Supplement 1): 4460.

https://doi.org/10.1182/blood-2021-149425

Published: 2021

Journal Articles

Properties and Distribution of IDH-1/2 Mutations in Acute Myeloid Leukemia By the Comprehensive Genomic Analysis

Blood (2021) 138 (Supplement 1): 4447.

https://doi.org/10.1182/blood-2021-149801

Published: 2021

Journal Articles

Genomic Analysis Focusing on RUNX1-RUNX1T1 in Japanese Patients with AML: HM-Screen-Japan 01

Blood (2021) 138 (Supplement 1): 4464.

https://doi.org/10.1182/blood-2021-148492

Published: 2021

Journal Articles

Hematologic Malignancies (HM)-Screen-Japan 01: A Mutation Profiling Multicenter Study on Patients with Acute Myeloid Leukemia

Blood (2021) 138 (Supplement 1): 4457.

https://doi.org/10.1182/blood-2021-149960

Published: 2021

Journal Articles

Clinical Significance of FLT3 Mutations in a Comprehensive NGS Multicenter Study of AML: HM-Screen-Japan 01

Blood (2021) 138 (Supplement 1): 2313.

https://doi.org/10.1182/blood-2021-146796

Published: 2021

Journal Articles

CPSF1-Mediated Acute Myeloid Leukemia Fusion 3'UTR Alternation Is a Potential Therapeutic Target

Takahiro Shima, MD PhD, Amanda G Davis, Daniel T Johnson, Yu Kochi, MD, Sayuri Miyauchi, DDS, PhD, Samuel A Stoner, Junichiro Yuda, MD, Toshihiro Miyamoto, MD PhD, Jie-Hua Zhou, MD, Edward D. Ball, MD, Koichi Akashi, MD PhD, Dong-Er Zhang, PhD

Blood (2018) 132 (Supplement 1): 885.

https://doi.org/10.1182/blood-2018-99-119199

Published: 2018

Journal Articles

Comparative Analysis of Tyrosine Kinase Inhibitors-Related Pulmonary Hypertension in the Patients Treated By Imatinib, Dasatinib and Nilotinib

Mariko Minami, MD, Toshihiro Miyamoto, MD PhD, Takeshi Arita, MD PhD, Tomohiko Kamimura, MD PhD, Junichiro Yuda, MD, Yoshikane Kikushige, MD PhD, Yasuo Mori, MDPhD, Goichi Yoshimoto, MD PhD, Kenjiro Kamezaki, MD PhD, Koji Kato, MD PhD, Motoaki Shiratsuchi, MDPhD, Katsuto Takenaka, MD PhD, Hiromi Iwasaki, MDPhD, Satoshi Yamasaki, MD PhD, Tsuyoshi Muta, MD PhD, Kazuki Tanimoto, MD PhD, Ryosuke Ogawa, MD PhD, Tetsuya Eto, MD PhD, Koichi Akashi, MD PhD

Blood (2015) 126 (23): 1583.

https://doi.org/10.1182/blood.V126.23.1583.1583

Published: 2015

Journal Articles

Persistence of Abnormally-Spliced, Functionally-Dead BCR-ABL Variants Is a Critical Obstacle to Achieve Sustained Complete Molecular Response in CML Patients: Results of a Quantitative, Highly-Sensitive, Deep Sequencing Study

Junichiro Yuda, MD, Toshihiro Miyamoto, MD PhD, Jun Odawara, MD PhD, Yoshikane Kikushige, MD PhD, Yasuyuki Ohkawa, PhD, Koichi Akashi, MD PhD

Blood (2014) 124 (21): 4525.

https://doi.org/10.1182/blood.V124.21.4525.4525

Published: 2014

Journal Articles

TIM-3 and Its Ligand, Galectin-9 Constitute a Pan-Myeloid Autocrine Loop to Develop and Maintain Malignant Stem Cells in Most Human Myeloid Leukemia

Yoshikane Kikushige, MD PhD, Junichiro Yuda, MD, Takahiro Shima, MD, Toshihiro Miyamoto, MD PhD, Koichi Akashi, MD PhD

Blood (2014) 124 (21): 835.

https://doi.org/10.1182/blood.V124.21.835.835

Published: 2014

Journal Articles

TIM-3, a Leukemia Stem Cell Marker, Plays a Role In Leukemic Transformation Through Autocrine Stimulatory Signaling By Its Ligand, Galectin-9

Yoshikane Kikushige, MD PhD, Junichiro Yuda, MD, Takahiro Shima, MD, Toshihiro Miyamoto, MD, Koichi Akashi, MD, PhD

Blood (2013) 122 (21): 4196.

https://doi.org/10.1182/blood.V122.21.4196.4196

Published: 2013

Journal Articles

Visualization Of Normal and Malignant Epigenetic Regulation In Hematopoiesis Utilizing Newly-Developed Histone Variant H3.3 Chipseq Analysis

Jun Odawara, MD, PhD, Kohta Miyawaki, MD, Junichiro Yuda, MD, Masayasu Hayashi, MD, Kazumitsu Maehara, PhD, Takahiro Shima, MD, Yoshikane Kikushige, MD, PhD, Yasuyuki Ohkawa, PhD, Koichi Akashi, MD, PhD

Blood (2013) 122 (21): 1189.

https://doi.org/10.1182/blood.V122.21.1189.1189

Published: 2013

Journal Articles

The Impact Of Novel Splicing Abnormalities Of BCR-ABL On The Pathogenesis Of CML

Junichiro Yuda, MD, Toshihiro Miyamoto, MD, Yoshikane Kikushige, MD, PhD, Jun Odawara, MD, PhD, Yasuyuki Ohkawa, PhD, Koichi Akashi, MD, PhD

Blood (2013) 122 (21): 5159.

https://doi.org/10.1182/blood.V122.21.5159.5159

Published: 2013

NARROW

Phase 1/2 Study of TP-3654, a Selective PIM1 Kinase Inhibitor: Preliminary Data Showed Clinical Activity and Cytokine Reductions in Relapsed/Refractory Myelofibrosis Patients

A Phase 1 Study of PIT565, a First-in-Class, Anti-CD3, Anti-CD19, Anti-CD2 Trispecific Antibody in Patients with Relapsed and/or Refractory B-Cell Malignancies

Phase 1/2 First-in-Human Study of the Menin-MLL Inhibitor DSP-5336 in Patients with Relapsed or Refractory Acute Leukemia

Mechanism of Late Recurrences of Chronic Myeloid Leukemia after Discontinuation of TKI Therapy: BCR::ABL1 Ins35bp Loss-of-Function Splicing Mutation and Regulatory T Cells

Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia

Preliminary Data from the Phase I/II Study of TP-3654, a Selective Oral PIM1 Kinase Inhibitor, in Patients with Myelofibrosis Previously Treated with or Ineligible for JAK Inhibitor Therapy

Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients with Acute Leukemia with and without Mixed-Lineage Leukemia (MLL)-Rearrangement (R) or Nucleophosmin 1 (NPM1) Mutation (m)

A Practice-Oriented Genome Profiling Study with the Novel Halo-Shape Annealing and Defer-Ligation Enrichment (HANDLE) System : HM-Screen-JAPAN02

Genomic Analysis of NPM1 Mutation and KMT2A ( MLL )-Rearrangement/Amplification in Japanese Patients with Acute Myeloid Leukemia: Hematologic Malignancies (HM)-Screen-Japan 01

Properties and Distribution of IDH-1/2 Mutations in Acute Myeloid Leukemia By the Comprehensive Genomic Analysis

Genomic Analysis Focusing on RUNX1-RUNX1T1 in Japanese Patients with AML: HM-Screen-Japan 01

Hematologic Malignancies (HM)-Screen-Japan 01: A Mutation Profiling Multicenter Study on Patients with Acute Myeloid Leukemia

Clinical Significance of FLT3 Mutations in a Comprehensive NGS Multicenter Study of AML: HM-Screen-Japan 01

CPSF1-Mediated Acute Myeloid Leukemia Fusion 3'UTR Alternation Is a Potential Therapeutic Target

Comparative Analysis of Tyrosine Kinase Inhibitors-Related Pulmonary Hypertension in the Patients Treated By Imatinib, Dasatinib and Nilotinib

Persistence of Abnormally-Spliced, Functionally-Dead BCR-ABL Variants Is a Critical Obstacle to Achieve Sustained Complete Molecular Response in CML Patients: Results of a Quantitative, Highly-Sensitive, Deep Sequencing Study

TIM-3 and Its Ligand, Galectin-9 Constitute a Pan-Myeloid Autocrine Loop to Develop and Maintain Malignant Stem Cells in Most Human Myeloid Leukemia

TIM-3, a Leukemia Stem Cell Marker, Plays a Role In Leukemic Transformation Through Autocrine Stimulatory Signaling By Its Ligand, Galectin-9

Visualization Of Normal and Malignant Epigenetic Regulation In Hematopoiesis Utilizing Newly-Developed Histone Variant H3.3 Chipseq Analysis

The Impact Of Novel Splicing Abnormalities Of BCR-ABL On The Pathogenesis Of CML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only